In development. Features, timelines and partnership models are subject to final settings and approvals. Figures marked as targets are indicative.
The translation gap · Australia · 2024
Women's Health Foundry is built and operated by Proto Axiom, the biotech incubator, and governed by an independent Advisory Board and Investment Review Committee — specialist de-risking, milestone-gated capital, and partner pathways for Australian women's health ventures.
Indicative synthesis of Australian public datasets; category definitions and reporting periods differ. Read the methodology note.
Submit a venture·Join the investor network·Explore partnership·Contribute lived experience
The gap
Across conditions that disproportionately affect women, disease burden routinely outruns research investment. The gap compounds down the pipeline: fewer programs, fewer clinical assets, fewer approvals.
Methodology note: indicative synthesis of NHMRC, MRFF and AIHW datasets, informed by Temkin et al. (2023). Categories and reporting periods differ between datasets; ratios are rounded and should be read as directional rather than audited totals.
Burden vs research spend, by category
% of national total
Reproductive & maternal
burden 9.2%·spend 1.1%·8.4× gap
Endometriosis & pelvic pain
burden 4.4%·spend 0.3%·14.7× gap
Cardiovascular (in women)
burden 11.8%·spend 2.9%·4.1× gap
Cancers (female-specific)
burden 7.1%·spend 4.2%·1.7× gap
Mental health (women)
burden 12.4%·spend 3.1%·4.0× gap
3.3%
Government research funding to women's health (FY2023–24)
$7.4–9.7B
Annual economic cost of endometriosis alone (UNSW & PwC)
4×
Median burden-to-spend gap in the categories above
The thesis
The Foundry is the operating layer. Capital rides on top — milestone-gated, co-invested, and governed by independent review. At Davos 2026, BCG and the World Economic Forum sized women's health as a US$100B+ market opportunity by 2030.
Program shape
Intakes
open national cohorts
Successive
SME funding
per SME, milestone-linked
Up to $5M
Co-investment
strategic, institutional, philanthropic
Required
Governance
investment + clinical review committees
Independent
I
Women's health is under-translated, not just under-funded. The gap between discovery and patient impact is an operations problem with measurable economic consequences.
II
Specialist milestones, regulatory maps, and partner networks outperform generic incubation across every stage of the pipeline.
III
Tranches tied to decision-grade de-risking — not undifferentiated runway — produce better portfolio-level outcomes and clearer stop points.
IV
Public investment unlocks matched strategic, institutional and philanthropic capital. Built with universities, health services, industry and consumers as shared infrastructure.
The mechanism
Ventures move from selection through staged de-risking to partner and capital pathways. Capital is released at gate reviews — up to $5M per SME, milestone-linked and non-dilutive.
01
Source & select
02
Stage 1 de-risking
03
Gate review
04
Stage 2 scale-up
05
Partner & capital
Why now, why us
The Foundry is the next scale of an operating platform already running. Staffing, selection process, review governance and partner network are in place — the mandate extends proven infrastructure to a specialist women's health cohort.
Operator track record
Proto Axiom has run translation programs across Australian universities and health services. Companies shaped through its incubation have gone on to raise A$170M+ in private capital and win $19.5M+ in competitive non-dilutive grants.
A$170M+
Private follow-on raised
$19.5M+
Non-dilutive follow-on
950+
People convened
200+
Applications reviewed
Category specialism
Specialist milestones, endpoints and evidence sequencing. Category review embedded at selection, not bolted on. Scope spans conditions that affect women uniquely, differently, or disproportionately — from endometriosis to cardiovascular and autoimmune disease.
3
Scope dimensions
14
Institutions engaged
4
States represented
100%
Consumer-reviewed selection
Mission fit
Moves Australian research through de-risking, evidence and commercialisation pathways into patient impact — directly addressing MRFF priorities around women's health, translation and the national research workforce. Co-investment structured for leverage, not substitution.
Co-invest
Required
Gated
Milestone capital
Independent
Review committees
National
Reach by design
Governance
Proto Axiom designs and runs the platform. Funding recommendations sit with an independent Investment Review Committee, overseen by an Advisory Board of national standing, with clinician, scientific and consumer panels reviewing evidence and ethics.
The Advisory Board
Sue MacLeman
Inaugural Chair — Chair of Medicines Australia; former CEO, MTPConnect
Professor Robyn Norton AO
Founding Director, The George Institute for Global Health
Professor Victoria Cogger
Executive Director, A$780M Sydney Biomedical Accelerator
Dr Steve Burnell
Managing Director, Tenmile (Tattarang)
Liza Noonan
CEO, Cicada Innovations
Ecosystem
Organisations active in this space
Institutions Proto Axiom has worked with through its translation programs and national events.
Insights
A 236-page history from Stifel's healthcare investment banking group lands as a bull thesis for the category Women's Health Foundry is built to serve. The signal matters more than the specifics — and Volume III, due later in 2026, is the one to watch.
6 min read
Australia has world-class research programs in reproductive biology, maternal health, and hormonal medicine. The challenge is converting that science into ventures that reach patients — and the infrastructure gap that sits between discovery and adoption.
10 min read
National platforms succeed when they strengthen — not bypass — universities, health services, industry, and investors. Shared milestones and governance-aware collaboration are how that works in practice.
6 min read
Register interest
We use this to prioritise outreach as the platform is finalised. Founders, partners, investors and community members each get a tailored brief.
Founders / researchers
Stage, category, and institution. We route to the right reviewer.
Partners / advisors
Sites, expertise, networks. Where you can contribute.
Investors / supporters
Tranches and timing. Updates on the anchor round.
Community / consumer
Lived experience and advocacy partners for review panels.